Skip to main content

Table 1 Demographic data and patient characteristics

From: Prognostic significance of DNMT3a gene expression and reactive nitrogen species in newly diagnosed Egyptian de novo adult acute myeloid leukemia patients

Patients characteristics Groups
Cases
(n = 45)
Control
(n = 10)
N % N %
Sex Male 24 53.3 5 50.0
Female 21 46.7 5 50.0
Age Range 20.0–78.0 33.0–50.0
Median (IQR) 50.0 (25) 41.50(10.5)
Peripheral blood TLC Range 1.0–236.0 6.0–9.0
Median (IQR) 10.0 (38) 7.0(2)
HB Range 4.0–12.0 10.0–14.0
Median (IQR) 8.0 (4) 12.0 (2.5)
PLT Range 4.0–345.0 189.0–370.0
Median (IQR) 40.0 (61) 230.50 (101.28)
P.B Range 0.0–87.0
Median (IQR) 32.0 (45)
B.M asp Range 30.0–99.0 -
Median (IQR) 70.0 (25) -
FAB. classification M0 1 2.2
M0–M1 1 2.2
M1 3 6.7
M1–M2 6 13.3
M2 8 17.8
M3 3 6.7
M4 2 4.4
M4–M5 16 35.6
M5 3 6.7
M7 2 4.4
Risk stratification Poor risk 7 15.5
Intermediate risk 25 55.5
Good risk 13 28.2
Remission status after induction chemotherapy Remitted 17 40.5
Refractory 8 17.8
Died 20 44.4
DNMT3A expression before treatment Range 18.60–83.60 0.54–1.72
Median (IQR) 46.5 (33.9) 0.98 (0.57)
DNMT3A expression after treatment Range 2.96–71.20
Median (IQR) 17.05 (37.4)
DNMT3A mutation Mutant 12 26.7
Wild 33 73.3
DNMT3A expression Low expression 22 48.9 10 100.0
High expression 23 51.1 0 0.0
NO level pre-treatment Range 0.53–60.90 0.0–22.11
Median (IQR) 12.0 (16.78) 5.80(9.65)
NO level post-treatment Range 0.0–27.50
Median (IQR) 6.20(8.8)
  1. HgB hemoglobin, NO nitric oxide, PB peripheral blood blast, PLT platelets, TLC total leucocytic count
  2. NB: the empty cells are for the unapplied points of comparison for the control grou